Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/050773external-prioritypatent/WO2010001169A2/en
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Publication of CU20100265A7publicationCriticalpatent/CU20100265A7/en
Publication of CU23957B1publicationCriticalpatent/CU23957B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a compuestos químicos de fórmula I, y sales de los mismos. En algunas realizaciones, la invención se refiere a inhibidores o moduladores de la actividad o función enzimática de la proteína quinasa PIM-I y/o PIM-2 y/o PIM-3. En otras realizaciones adicionales, la invención se refiere a composiciones farmacéuticas que comprenden compuestos descritos en la presente y su uso en la prevención y tratamiento de afecciones y enfermedades relacionadas con la quinasa PIM, preferiblemente cáncer.The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of the enzymatic activity or function of the protein kinase PIM-I and / or PIM-2 and / or PIM-3. In other further embodiments, the invention relates to pharmaceutical compositions comprising compounds described herein and their use in the prevention and treatment of conditions and diseases related to PIM kinase, preferably cancer.
CU2010000265A2009-06-022010-12-29
DERIVATIVES OF TIAZOLIDIN-2,4-DIONA
CU23957B1
(en)
DERIVATIVES OF ANILINA-PYRIMIDINE SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE DEPENDENT KINASES (CDK), PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS